Clean Science and Technology Limited — Investor Meet, 03-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: In Q3 FY25, Clean Science and Technology reported steady revenue with total sales reaching Rs. 240 crore, reflecting a 20% year-over-year increase. The EBITDA improved by 14% to Rs. 98 crore, resulting in a reported EBITDA margin of 41.5%. Net profit rose 5% to Rs. 66 crore, with a PAT margin of 27.5%. Notably, EBITDA increased by 8% quarter-over-quarter, leading to a margin of 45%, while net profit saw a 10% rise.

2. Future Outlook and Growth Drivers: Management highlighted growth potential driven by the scaling up of the HALS product line and commercialized pharmaceutical intermediates, including DHDT. The focus is on expanding market presence and enhancing product offerings to meet client needs.

3. Order Book and Operational Updates: The HALS product line achieved a monthly sales volume of approximately 190 tons, with diversification into additional HALS products expected to boost revenue. The company also launched DHDT, enhancing its pharmaceutical segment.

4. Analyst Q&A Insights (Detailed):

- Revenue and Profitability: Analysts inquired about revenue projections and margin expectations. Management indicated margins benefited from decreased raw material costs rather than price hikes.

- Market Position and Competitive Landscape: Questions addressed the competitive threats from established players like BASF. Management remains optimistic about leveraging technological advantages and securing market share.

- Operational Challenges or Risks: Analysts raised concerns regarding supply chain and production challenges. Management's confidence in overcoming these issues was evident, especially by reallocating production capacities.

- Capex and Capital Allocation: Discussions focused on the company’s significant CAPEX plans of Rs. 150 crore for performance chemical production, anticipating Rs. 80-90 crore in revenue from these investments.

- Strategic Priorities and Long-Term Vision: Analysts probed into long-term strategies, including sustainability initiatives and market expansion. Management signaled an ongoing focus on innovation and diversifying product offerings.

5. Market or Regulatory Updates: There were no prominent regulatory changes noted that could impact operations. The focus remained on market demand and production scaling.

6. Strategic Focus Areas: Clean Science aims for continuous innovation and cost management while capitalizing on its unique technology to expand in both domestic and international markets.

7. Investor Insight: The overall financial performance and growth trajectory suggest a positive outlook. The company's strategic initiatives align with potential growth opportunities, indicating a favorable position for investors considering a ‘buy’ stance.